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Genotype DQ2.5/DQ2.2 (𝛽2/𝛽2)  
and High Celiac Disease Risk 
Development
Yanna Karla de Medeiros Nóbrega
Abstract
Celiac disease (CD) is a genetically determined immune-mediated disorder in 
which gluten immunogenic peptides are presented to CD4 T cells by HLA-DQ2.5, 
DQ8, DQ2.2, and their combinations. CD is considered one of the most well-
characterized autoimmune diseases, having a described environmental factor, a 
well-established pathogenesis, associated genetic factors, and a well-established 
laboratory diagnosis, although it is still considered a difficult-to-classify disease. In 
the last decades, advances in laboratory diagnosis with the emergence of molecular 
biology techniques have allowed a specific characterization of the CD-associated 
genotypes and, although clinically the disease management was not modified 
by this factor, the follow-up of patients at risk of CD development has greatly 
benefited from the possibility of specifically finding the inherited genotype, and 
whether it represents a greater or lesser risk for developing the disease. In some 
populations, it is already possible to calculate the exact risk associated to the 
inherited genome by each individual, but the genotypes available in several coun-
tries sometimes disregard the relevance of searching beyond the genotypes DQ2.5/
DQ2.5, DQ2.5/DQ8, and DQ2.5/DQ2.2, which also present a high risk for developing 
the disease.
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1. Introduction
1.1 Definition, prevalence, and classification
Celiac disease (CD) is a genetically determined immune-mediated disease, and 
individuals with CD have specific HLA haplotypes (DQ2 and/or DQ8) that trigger 
an immune response to gluten intake, leading to intestinal and clinical signs and 
symptoms [1, 2], besides other autoimmune-associated CD diseases, such as derma-
titis herpetiformis [3], type 1 diabetes mellitus, Hashimoto’s thyroiditis, and Sjögren 
syndrome [4]. Also, there are some genetic syndromes that may be CD associated 
such as Down syndrome [5, 6], Turner syndrome [7], and Williams syndrome [8].
As CD is one of the most well-elicited autoimmune diseases and one of the 
most common permanent food intolerances among humans [9], its prevalence in 
the general population from Europe, USA, and countries where the population is 
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predominantly of European origin is approximately 1% [2]. Prevalence is lower, 
ranging from 0.15 to 0.84%, in Latin American countries such as Brazil [10–14]. 
When Brasília city (Brazilian capital and population representation) is considered, 
since it is a city formed by people from all regions of the country, the prevalence 
found in the general population is 0.34%, considering 0.21% in adults and 0.54% in 
children [11].
The CD prevalence can still be related to the cereal consumption that contains 
gluten (mainly wheat) and to the distribution of predisposing HLA alleles in the 
population  [15, 16]. Besides, the existence of genetic and environmental factors 
may influence the CD prevalence rate in a region [15]. Last but not least, we high-
light the microbiota variability, the existence of intestinal infections, and socioeco-
nomic conditions, which are also factors that may influence the CD development 
and prevalence [17, 63].
According to clinical signs and symptoms, laboratory and histopathological 
findings, which together have been called “clinical forms,” CD can be classified into 
five distinct forms (Table 1).
1.2 CD pathogenesis and immune response (IR), the HLA importance
CD pathogenesis, which is an inflammatory enteropathy with autoimmune 
characteristics, is triggered by gluten ingestion [17]. In nonceliac individuals, gluten 
is cleaved by digestive enzymes into small fragments for eliciting an immunogenic 
response and is digested by gastrointestinal system without causing damages. In 
CD patients, the gluten digestion induces gliadin fragments initiating an innate and 
adaptive immune response resulting in tissue damage of the intestinal mucosa and 
clinical CD manifestations [24].
Classification Clinical forms
Classic or typical Frequently in children, characterized by gastrointestinal manifestations that can 
arise after the introduction of gluten foods (weeks, months, or even years). Patients 
have positive serology for CD and HLA compatible; and, in intestinal biopsy, there 
are usually lesions of variable severity, but they are frequently characterized by 
hypotrophy or atrophy of intestinal villi and varying degree of intestinal cryptic 
hyperplasia.
Atypical or 
nonclassical
Minimal or no gastrointestinal manifestations and recurrent extraintestinal 
manifestations. It can appear at any age (but commonly in teenagers and adults). It 
presents positive serology, HLA, and CD-compatible biopsy.
Silent or 
asymptomatic 
(subclinical)
Signs and manifestations commonly associated to CD are nonexistent. Patients are 
diagnosed occasionally in screening programs or because they are in risk CD groups 
(carriers of autoimmune diseases or celiac relatives), by positive serology, HLA, and 
CD compatible biopsy.
Potential Patient may or may not present manifestations, as well as may not develop mucosal 
lesions in the future. CD-positive serology, CD-compatible HLA typing, normal 
intestinal mucosa, or with subtle abnormalities (increase of intraepithelial 
lymphocytes) and absence of significant enteropathy.
Latent 
(controversy)
Characterized by the presence or absence of antibodies in the normal intestinal 
mucosa, HLA typing is CD compatible, but for being defined as having CD, there 
must be a prior diagnosis of at least the presence of an enteropathy associated to 
gluten consumption.
Adapted from Fasano and Catassi, [18]; Lionetti and Catassi [17]; Admou et al. [19]; Bao, Green and Bhagat [20]; 
Husby [8]; Kaneepkens and von Blomberg [21]; Ludvigsson et al. [22]; Sapone et al. [23].
Table 1. 
Celiac disease classification and clinical forms.
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Gluten is the energy storage protein found in wheat, rye, barley, and oat grains, 
which has a large amount of prolamins (glutamine and proline) in its primary 
structure. Proline-rich peptides are resistant to gastrointestinal digestion [25].
Specifically in wheat, gluten proteins are divided into gliadins and glutenins 
[25], according to the solubility of the prolamins present. Gliadin is soluble in 
alcohol, while glutenin is soluble in acidic and basic dilutions [26]. Gliadin is an 
alcohol-soluble, 30 kDa protein, particularly rich in glutamine and proline residues, 
which are contained in polyglutamine sequences, represented as a single chain 
of polypeptides, which can be divided in four different groups: α-, β-, γ-, and 
Ω-gliadin [26]. The N-terminal domain of α-gliadin contains the most immunogenic 
fragment, which has the peptide 31–43 and the 33-mer fragment, which contains six 
significant epitopes for CD pathogenesis [27, 28].
The presence of gliadin and its peptides is the external factor triggering the 
immune response in CD, which implies the need for its entry through the mucosa 
and presence in the lamina propria with consequent obligatory passage through 
the cells of the intestinal epithelium. This epithelium entry occurs by three 
mechanisms: (1) through the transcellular route, where gluten is endocytosed in 
lysosomes, which degrade it in small nonimmunogenic peptides [29]; (2) via the 
paracellular route, by regulating the TJ junctions responsible for the union of the 
epithelial cells, promoting a change in cellular permeability and, consequently, 
the entry of gliadin peptides into the mucosa, such as regulation through zonulin 
produced by epithelial cells of celiac patients that alter the permeability between 
epithelial cells [29, 30]; (3) by transepithelial transport in cells of celiac patients, 
where there is an increase in CD71 (transferrin receptor) expression. This receptor 
recognizes IgA complexed with gliadin through the Fc portion of the immuno-
globulin, and releases this association without processing in the lamina propria [31].
Although these mechanisms of entry and processing by digestive enzymes 
are described in the literature, it is believed that these peptides interact with the 
intestinal epithelial cells and produce an inflammatory response before presenting 
themselves in the lamina propria, promoting gene alterations in this cell by mecha-
nisms not yet fully elucidated [24].
In an in vitro cellular CD model by using CaCo2 cells, intact gliadin and its 
immunogenic peptides from the 33-mer fragment (nondeaminated—P56-88, 
P57-68, P69-82, P31-43, and deaminated P57-68 E65 and P69-82 E72) were used for 
understanding this interaction mechanism in the first 24 and 48 h. Results showed 
that following interaction with CaCo2 cells, these peptides modulated receptor gene 
transcripts such as TLR-4, cell permeability altering protein genes such as zonulin 
and occludin, as well as inflammatory cytokines (IL-1, IL-6, IL-8, and IL-15) very 
important for CD pathogenesis, besides increasing the production mediators of 
oxidative stress such as nitric oxide. Afterward, IL-6 and TNF-α levels revealed 
the secretion of these cytokines in culture supernatant, confirming the inflamma-
tory process initiated in the first 24 and 48 h after interaction with these human 
epithelial cells when culture (unpublished data) [32]. Earlier data had previously 
confirmed that the peptide p31-43 activates the innate immune response through 
the activation of proinflammatory cytokines, while the p57-68 peptide has been 
identified as immunodominant and capable of activating the adaptive immune 
response through recognition by T cells-CD4 [33].
When gliadin peptides reach the lamina propria, they are modified by the action 
of the tissue transglutaminase 2 (tTG2) enzyme, which in the presence of calcium, 
converts glutamine residues to glutamic acid, the negative charge of glutamic 
acid increases the affinity of tTG2 for gliadin and the gliadin-tTG2 complex also 
increases the affinity of the gliadin-tTG2 complex and the gliadin peptides with the 
MHC class II molecules HLA-DQ2/DQ8 [15, 34–36].
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These gliadin peptides are recognized and processed by the HLA-DQ2/DQ8 
MHC class II antigen presenting cells (APCs) and are presented to CD4 T cells, 
which become active and begin to produce IFN-γ and IL-15. T-CD4 lymphocytes, 
activated by APCs on the lamina propria, differentiate into intraepithelial lympho-
cytes (IELTs) and infiltrate epithelial cells in response to IL-15 stimuli produced 
by enterocytes. Also, in response to IL-15, IELTs display cell membrane receptors 
for natural killers (NK), which promotes the cascade recruitment of new NK 
cells, which promote destruction of the epithelial barrier, cryptic hyperplasia, and 
atrophy of the intestinal villi [25, 37, 38].
APCs migrate to the mesenteric lymph node and display the gliadin peptides 
complexed with tTG2 to immature CD4 T cells. In mesenteric nodules, T-CD4 cells 
differentiate into effector T-CD4 cells (T-CD4+), which increases the proliferation 
of reactive B cells to the gliadin-tTG2 complex. Reactive B cells differentiate into 
plasma cells and produce IgA and IgG antibodies, not only against glutamine resi-
dues modified to glutamic acid, but also against tTG2, which may still be complexed 
with these peptides [39, 40].
The continuous recognition by APCs of the gliadin-tTG2 complex as an immu-
nogenic stimulus accentuates the immunological and proinflammatory response, 
triggering the autoimmune response found on CD [8]. However, in healthy 
individuals, the recognition of these peptides when presented by MHC of class II 
originated of HLA DQ2/DQ8 [41] also occurs.
The entire inflammatory process induced by gliadin and its peptides on CD is a 
result from the synergism between the innate and adaptive immune response that 
occurs in two distinct sites in the small intestine, that is, in the epithelium and in the 
intestinal lamina propria [31, 42].
Studies suggest that CD is primarily mediated by adaptive immunity, where CD4 
T cells recognize gliadin peptides through MHC II molecules, which are encoded by 
the HLA (Human Leukocyte Antigen) DQ2 and DQ8 genes present in celiac patients, 
which confirms the strong genetic basis [15, 31, 42].
For all these reasons, CD is an excellent model for studying the genetic factors 
that contribute to the development of immune-mediated disorders. Among these 
reasons, we can highlight the fact that it has a well-known environmental triggering 
factor—gluten, an autoimmune disease with a well-described genetic predisposition 
associated to the MHC HLA DQ2/DQ8 alleles, the involvement existence of other 
non-MHC genes, and the high incidence of other immunological diseases reported 
in both celiac and familial patients, in which the innate and adaptive response 
plays a key role [43]. CD is also considered a multifactorial disease caused by the 
interaction of different genetic factors that act in consonance with nongenetic 
effects, since nonceliac individuals also have such alleles, suggesting that additional 
complementary mechanisms are necessary for the disease development [39].
Similar to other autoimmune diseases, CD is a polygenic disorder and the MHC 
gene is the most important genetic factor. Most celiac patients carry a specific 
genetic variance of HLA-DQ2 (DQA1 * 05: 01, DQB1 * 02: 01, known as DQ2.5), and 
those who are not HLA-DQ2.5 almost always carry the HLA variance -DQ8 (DQA1 *  
03, DQB1 * 03: 02) or another variant of HLA-DQ2 (DQA1 * 02: 01, DQB1 * 02: 02), 
known as DQ2.2 [9]. Since all celiac patients carry specific HLA variations, this 
factor may be considered necessary for CD diagnosis, but alone it is not sufficient 
for CD development [25].
Recently, studies based on Genome Wide Association Studies (GWAS) has been 
allowing the identification of single-nucleotide polymorphisms (SNPs) in each gene 
in the human genome associated to a cell metabolic pathway or a specific phenotype 
such as CD. In general, GWAS tests hundreds of thousands of SNPs throughout 
the patient genome and matched the control ethnic group [44]. These SNPs often 
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affecting the recognition of transcription factors, resulting in differences in the 
expression of regulatory genes shared with other autoimmune diseases. After 
GWAS studies, it was possible to verify by immunochip analysis that several non-
MHC genes have been related as CD susceptibility factors. Until then, 39 loci with 
57 independent association signals were described, contributing 14% of the genetic 
variance for CD [45].
Many of these genetic variances are shared with other autoimmune diseases such 
as type 1 diabetes mellitus and rheumatoid arthritis [46]. After GWAS studies, once 
evidenced correlations with metabolic pathways and shared inflammatory response 
between CD and other autoimmune diseases, new strategies that make use of differ-
ent cellular models can be applied to CD [47].
1.3 Laboratory diagnosis and HLA determination relevance
Clinical CD manifestations are very heterogeneous and often subtle, which 
may confuse the clinician and delaying the definitive diagnosis. According to 
the European Society for Pediatric Gastroenterology Hepatology and Nutrition 
(ESPGHAN), CD diagnosis depends on clinical manifestations, significant level of 
the presence of specific antibodies (positive serology), presence of predisposing 
HLA-DQ2 and/or HLA-DQ8 genes, and presence of histopathological abnormalities 
from the intestinal mucosa evidenced by the biopsy [8].
ESPGHAN advises that CD diagnosis should be considered in children and 
adolescents who present gastrointestinal (diarrhea, abdominal pain, nausea, vomit-
ing, etc.) and extraintestinal manifestations (anemia, dermatitis herpetiformis, 
chronic fatigue, etc.). It is also recommended that CD diagnosis be evaluated in 
asymptomatic children and adolescents (but belong to a risk group for CD develop-
ment). Risk CD groups are composed of individuals with type 1 diabetes, Down’s 
syndrome, Turner’s syndrome, Williams’s syndrome, autoimmune thyroid disease, 
autoimmune liver disease, selective IgA deficiency, and first-degree relatives of 
celiac [8]. American Gastroenterology Association recommends that CD diagnosis 
be considered in any individual with a clinical condition indicative of CD or belong-
ing to at-risk groups [48].
The production of anti-endomysium (EMA), anti-gliadin, antitransglutaminase 
(anti-tTG) and gliadin-tTG complexes is part of the CD pathogenesis process. 
Serological tests used in the laboratory CD diagnosis are intended to detect levels 
of these antibodies in the serum (CD-suspected individuals). The available CD 
diagnostic tests include anti-gliadin IgA and IgG antibodies, anti-EMA IgA and IgG, 
IgA and IgG anti-tTG [48, 49].
Anti-gliadin antibodies are not currently considered sufficiently sensitive or 
specific to be used in the CD diagnosis [20] and have been replaced by anti-gliadin 
deaminated (anti-DGP) antibodies of both IgA and IgG because they have greater 
sensitivity and specificity. Anti-DGP IgG test is used in IgA deficiency cases where 
anti-DGP IgG antibodies are detected [49]. Both IgA and IgG anti-DGP assays are 
commonly used as additional tests in patients who are negative for other serologi-
cal tests but presenting characteristic clinical CD symptoms, especially in patients 
younger than 2 years old [8, 49].
Anti-tTG antibodies are commonly detected by ELISA method usually by 
human recombinant tTG as antigen [8]. Anti-tTG IgA serological test is considered 
the most sensitive method for diagnosing CD, with sensitivity close to 97% [20]. 
This test has high specificity, close to 99% [48]. Although anti-tTG IgA assay 
has high sensitivity and specificity, it is possible to find false-positive results in 
patients with liver disease, congestive heart failure, arthritis, and inflammatory 
bowel disease [48]. Anti-tTG IgA test is generally used as the first test in the initial 
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approach for diagnosing CD because it is a quantitative test that can be automated 
and does not depend on the observer interpretation such as the anti-endomysium 
test [8, 49].
Although the main methodology used for dosing tTG and gliadin is performed 
by ELISA, in the last two decades, new methodology is available; it is worth men-
tioning the indirect chemiluminescence immunoassay (CLIA) [50, 51] and the 
fluorescent enzyme immunoassay (FEIA or EliA) [52].
IgA-EMA antibodies are detected by indirect immunofluorescence, which 
requires microscopic evaluation. This method is of subjective evaluation, being 
subject to variations depending on different observer interpretations. However, 
when well interpreted by the experienced observer, the specificity of the IgA-EMA 
serological test is close to 100% [48], being considered a reference test for detecting 
specific CD antibodies [8].
For the anti-endomysium (EMA), although new methods have not been devel-
oped, it is now possible to carry out the technical procedure in a fully automated 
way, and reading by integrated software. Even with this great advance and agility 
in sample processing time, and in the technical standardization of the employed 
method, the existence of characteristic fluorescence patterns still requires that the 
analyzes be interpreted according to the knowledge and subjective observation 
of the microscopist or the observed, which causing high intra- and interlabora-
tory variability, which in laboratory practice is considered the major problem for 
diagnosing autoimmune diseases in general.
Also, the use of molecular methodologies in the laboratory diagnosis currently 
allows the detection of HLA genotypes associated to CD, in a highly specific way, 
mainly using the RT-PCR methodology.
1.4 HLA and the importance of risk genotypes in laboratory genotyping
CD is an example of a multifactorial disorder in which the genetic test is of great 
clinical relevance, since the disease rarely develops in the absence of HLA-specific genes 
(HLA-DQ2 and HLA-DQ8) [15, 53]. The HLA-DQ2 and HLA-DQ8 genes are required 
for developing CD but are not sufficient [54]. If an individual carries these genetic 
markers, it does not necessarily mean that the subject will develop CD, but having a 
risk for developing the disease. Therefore, the absence of the HLA-DQ2 and HLA-DQ8 
genes has a high negative predictive value for the diagnosis of CD, ie, the chance of an 
individual who does not have these genes develop CD is extremely low, whereas the 
presence of these genes markers has a relevant positive predictive value [55].
HLA typing can be used to rule out the diagnostic hypothesis of CD in patients 
with doubtful diagnosis, excluding the disease possibility in individuals who do not 
have these genes. Chang and Green [53] suggested that HLA typing be performed 
prior to serological testing to reducing the number of false-positive results and 
thereby decreasing the number of biopsies required. However, ESPGHAN recom-
mends that the HLA test be performed prior to the serological tests only in the case 
of asymptomatic patients belonging to risk groups (first-degree relatives of celiac, 
type 1 diabetic patients, and Down syndrome, for example) [8].
In CD, the heterodimers are called human leukocyte antigen (HLA) and belong 
to HLA-DQ loci present on chromosome 6. Genotypes that are strongly associ-
ated to the onset of the immune response triggered by gluten are HLADQ2.5, 
HLA-DQ2.2, and HLA-DQ8 [56–58]. It is known that genotypes HLA-DQ2.5 (DQA1 
* 05: 01, DQB1 * 02: 01), HLADQ2.2 (DQA1 * 02: 01, DQB1 * 02: 02), and HLA- 
DQB1 * 03: 02) are necessary but not sufficient for developing CD, since more than 
30% of the general population in the world have these genotypes and only 3–5% 
will develop CD [9, 59–61].
7Genotype DQ2.5/DQ2.2 (𝛽2/𝛽2) and High Celiac Disease Risk Development
DOI: http://dx.doi.org/10.5772/intechopen.80578
Virtually, all CD patients carry the alleles encoding the HLA-DQ2 and/or DQ8 
molecules or at least one DQ2 heterodimer chain, usually the DQB1 * 02 allele-
encoded strand. The CD occurrence in the absence of these risk factors in DQ 
is extremely rare, but the presence of these molecules also fails to predict with 
precision when and if the CD will develop, since they are present in 25–50% of the 
general population, although the vast majority of these individuals never develop 
the disease throughout life [58].
Even with this knowledge, performing HLA-DQ typing for determining future CD 
risk has been widely discussed, although its practical use is mostly associated to risk 
groups where genetic testing of individuals could eliminate the need for future antibody 
tests in more than 60% of the population considered to be at low CD risk (DQ2 or DQ8 
negative). On the other hand, the identification of high-risk individuals would allow 
a safer prospective screening, allowing an early therapeutic intervention [5], and a 
more precise monitoring, since the risk of developing the disease is more likely in these 
individuals. In the scientific literature, the first study that calls attention to the determi-
nation of CD risk development associated to the presence of HLA-DQ genotypes was 
performed by Megiorne et al. [62] in the Italian population, the best characterized thesis 
in the world. Results showed that considering the prevalence of 1: 100 established in this 
population, which corresponds to 1% that is the prevalence in populations of Caucasian 
origin in the world population, the risks for developing CD were higher when associated 
to the presence of genotypes DQ2.5/DQ2.5 and DQ2.5/DQ2.2, in addition to DQ2.5/
DQ8, where the risk found was 1: 7, 1:10, and 1:24 (Figure 1).
After this publication, rare study has appeared, is the case of Almeida et al. [2] 
and Murad et al. [64], that given the existence of the estimated prevalence of these 
populations in other studies in the same region, were able to calculate the CD risk 
development in the populations of Brazil and Syria, respectively.
Results found by Almeida et al. [2] showed that the risks associated to DQ2.5/
DQ2.5, DQ2.5/DQ2.2 and DQ2.5/DQ8 genotypes in the Brazilian population were 
1:7, 1:10, and 1:19, respectively, such as described by Megiorni et al. [62].
Murad et al. [64] found in the Syrian population, a slightly different risk for 
DQ2.5/DQ2.5, DQ2.5/DQ2.2, and DQ2.5/DQ8 genotypes and the associated risks 
were, respectively, 1:12.5, 1:20, and 1:10, emphasizing that in this population of 
origin other than Caucasians, the risk associated to these genotypes are somewhat 
different in terms of prevalence, but they continue to confer the greatest risks for 
developing CD (Figures 2 and 3).
Figure 1. 
Risk calculated by Megiorni et al. [62] in the Italian population. Adapted from Megiorni et al. [62].
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Because it is not possible to calculate the risk for the various world populations, 
there are many where the absence of disease prevalence data does not allow this 
calculation to be carried out, an estimate for populations of Caucasian origin seems 
to produce very close results suggesting that calculations are accurate in these 
populations. Considering the relevance of risk demonstrated by the most prevalent 
and important genotypes for the development of CD, DQ2.5/DQ2.5, DQ2.5/DQ2.2, 
and DQ2.5/DQ8, it can be recommend that population studies, especially those for 
clinical diagnosis, which until now considering the risk for  development CD associ-
ated only to the presence of the DQ2.5/DQ2.5 and DQ2.5/DQ8 genotypes, which 
consider the inclusion of the DQ2.5/DQ2.2 genotype in their research, because 
this genotype does indeed pose a high risk for CD development and should not be 
neglected.
Figure 3. 
Calculated Risk—Murad et al. [64].
Figure 2. 
Calculated Risk (Brazilian population)—Almeida et al. [2].
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